These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Chronic kidney disease--mineral and bone disorder: why and how to control phosphate]. Pavlović D; Katicić D; Josipović J Acta Med Croatica; 2012 Oct; 66 Suppl 2():64-7. PubMed ID: 23513419 [TBL] [Abstract][Full Text] [Related]
6. Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic. Hu L; Napoletano A; Provenzano M; Garofalo C; Bini C; Comai G; La Manna G Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293076 [TBL] [Abstract][Full Text] [Related]
7. Phosphate restriction using a processed clay mineral reduces vascular pathologies and microalbuminuria in rats with chronic renal failure. Hofrichter J; Sempert K; Kerkhoff C; Breitrück A; Wasserkort R; Mitzner S BMC Nephrol; 2022 Apr; 23(1):162. PubMed ID: 35484519 [TBL] [Abstract][Full Text] [Related]
8. Relationship Between Dietary Phosphate Intake and Biomarkers of Bone and Mineral Metabolism in Australian Adults With Chronic Kidney Disease. Conley M; Campbell KL; Hawley CM; Lioufas NM; Elder GJ; Badve SV; Pedagogos E; Milanzi E; Pascoe EM; Valks A; Toussaint ND J Ren Nutr; 2022 Jan; 32(1):58-67. PubMed ID: 34509358 [TBL] [Abstract][Full Text] [Related]
9. [Chronic kidney disease - Mineral bone disorders: Physiopathology and guidelines]. Lavainne F; Guillot P; Figueres L Rev Med Interne; 2022 Apr; 43(4):225-232. PubMed ID: 35227526 [TBL] [Abstract][Full Text] [Related]
10. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial. Sigrist M; Tang M; Beaulieu M; Espino-Hernandez G; Er L; Djurdjev O; Levin A Nephrol Dial Transplant; 2013 Jan; 28(1):161-9. PubMed ID: 23024219 [TBL] [Abstract][Full Text] [Related]
11. Effect of nutritional calcium and phosphate loading on calciprotein particle kinetics in adults with normal and impaired kidney function. Tiong MK; Cai MMX; Toussaint ND; Tan SJ; Pasch A; Smith ER Sci Rep; 2022 May; 12(1):7358. PubMed ID: 35513558 [TBL] [Abstract][Full Text] [Related]
12. [Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)]. Iwashita Y; Iwashita Y; Ito T; Shigematsu T Clin Calcium; 2016 Feb; 26(2):259-67. PubMed ID: 26813506 [TBL] [Abstract][Full Text] [Related]
13. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification. Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993 [TBL] [Abstract][Full Text] [Related]
14. Risk factors and implications associated with renal mineralization in chronic kidney disease in cats. Tang PK; Jepson RE; Chang YM; Geddes RF; Hopkinson M; Elliott J J Vet Intern Med; 2022 Mar; 36(2):634-646. PubMed ID: 35043997 [TBL] [Abstract][Full Text] [Related]
18. IL-1β Drives Production of FGF-23 at the Onset of Chronic Kidney Disease in Mice. McKnight Q; Jenkins S; Li X; Nelson T; Marlier A; Cantley LG; Finberg KE; Fretz JA J Bone Miner Res; 2020 Jul; 35(7):1352-1362. PubMed ID: 32154933 [TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Manghat P; Fraser WD; Wierzbicki AS; Fogelman I; Goldsmith DJ; Hampson G Osteoporos Int; 2010 Nov; 21(11):1853-61. PubMed ID: 20012018 [TBL] [Abstract][Full Text] [Related]
20. [Chronic kidney disease (CKD) and bone. The mechanisms of chronic kidney disease--mineral and bone disorder (CKD-MBD)]. Hamada Y; Fukagawa M Clin Calcium; 2009 Apr; 19(4):486-92. PubMed ID: 19329826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]